TrialBritish journal of clinical pharmacology2016

First-in-human study assessing safety, tolerability and pharmacokinetics of BI 409306, a selective phosphodiesterase 9A inhibitor, in healthy males.

Viktoria Moschetti et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.